Loading...
XSHG
603309
Market cap485mUSD
Oct 09, Last price  
11.26CNY
1D
1.08%
1Q
-4.74%
Jan 2017
-42.17%
IPO
19.98%
Name

Well Lead Medical Co Ltd

Chart & performance

D1W1MN
XSHG:603309 chart
P/E
43.06
P/S
2.01
EPS
0.26
Div yield, %
4.49%
Shrs. gr., 5y
2.50%
Rev. gr., 5y
7.60%
Revenues
1.63b
+8.07%
348,235,226387,220,714437,167,108496,414,400548,871,061515,419,905629,894,883745,834,592993,812,5561,130,678,8091,118,570,9381,363,352,5531,387,735,3501,509,335,2551,631,174,995
Net income
76m
-65.21%
47,924,93155,609,40363,585,72767,819,98391,324,90179,249,98464,557,09565,403,011121,144,869153,110,857106,093,295166,571,293192,485,122219,393,02576,327,701
CFO
330m
+7.84%
44,075,92783,234,11372,853,113107,343,45181,466,12385,348,01574,343,82889,888,862178,794,590228,443,989187,283,077391,125,593233,512,282306,259,194330,255,209
Dividend
May 28, 20260.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Well Lead Medical Co., Ltd. specializes in the comprehensive process of researching, producing, and commercializing medical catheters. These essential devices serve critical applications in various fields such as anesthesia, urology, respiratory care, and hemodialysis. The company's product portfolio also extends to drainage, suction, and nutritional delivery systems. Its offerings are integral to hospital environments, supporting surgical operations, therapeutic interventions, and both emergency and routine clinical patient management. Founded in Guangzhou, China, in 2004, the firm boasts a significant global presence, distributing its solutions across key markets including China, North America, Europe, and Japan.

Key people

Guangyuan Han
Vice Chairman of the Board, General Manager · since 2011
Yimin Zhu
Chief Financial Officer · since 2021
Bin Chen
Deputy General Manager, Secretary of the Board · since 2022
Yungui Chen
Deputy General Manager, Director · since 2020
Songfeng Duan
Deputy General Manager, Director · since 2011
Jie Shu
Staff Elected Director · since 2025
Bin Xiang
Chairman of the Board · since 2011
Chunbin Lu
Independent Director · since 2023
Independent Director · since 2023
Chuanbao Zang
Independent Director · since 2023
IPO date
Mar 02, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT